本人主要从事活性分子筛选与抗肿瘤机制研究；硒基药物在抗氧化应激、抗肿瘤免疫治疗、纳米疫苗和临床免疫功能调控中的研究。目前已以第一作者和共同第一作者身份在 Signal Transduction and Targeted Therapy（IF=38.12）, ACS Nano（IF=18.027）, Biomaterials（IF=15.304）, Theranostics（IF=11.6）, Chemical Engineering Journal IF=16.744）, Chemical Communications（IF=6.222）和Chemistry-An Asian Journal（IF=4.839）等杂志发表学术论文12篇，其中SCI一区、影响因子10分以上的学术论文5篇。获得了国家自然科学基金青年基金（2022）、中国博士后科学基金资助（2021）和暨南大学华侨医院博士后启动基金（2021）的资助。参与申报中国专利2项，PCT专利1项。
06/2023-至今， 暨南大学化学与材料学院，副研究员
07/2020-05/2023，暨南大学第一临床医学院，博士后，肿瘤学
09/2017-06/2020，暨南大学，博士，生物医药
08/2014-08/2017，暨南大学化学与材料科学学院，研究助理
09/2011-06/2014，暨南大学，硕士，生物化学与分子生物学
09/2011-06/2007，广东药科大学，学士，生物制药
1.国家自然科学基金委员会，青年科学基金项目，32101044，硒调控自然杀伤细胞脂类代谢重编程在肿瘤免疫治疗中的应用与机制研究，2022-01-01至2024-12-31，30万元，在研，主持；
2.中国博士后科学基金：基于功能化纳米硒的脂类代谢调控在肿瘤免疫治疗中的应用研究，2020M681372，2020-11至2022-10，8万元，在研，主持；
1. Haoqiang Lai; Ligeng Xu*; Chang Liu; Sujiang Shi; Yalin Jiang; Yangyang Yu; Bo Deng; Tianfeng Chen*. Universal selenium nanoadjuvant with immunopotentiating and redox-shaping activities inducing high-quality immunity for SARS-CoV-2 vaccine.Signal Transduction and Targeted Therapy.2023, 8, 88.（IF=38.12, A1一区）
2. Chang Liu #, Haoqiang Lai # (co-first author),and Tianfeng Chen*. Boosting Natural killer cell-based cancer immunotherapy with selenocystine/transforming growth factor-beta inhibitor encapsulated nanoemulsion. ACS Nano. 2020, 14, 9, 11067–11082（IF=18.03, A1一区）
3. Haoqiang Lai #(co-first author), Xiaobin Zhang #, Zhenhuan Song, Zhongwen Yuan, Lizhen He⁎, Tianfeng Chen⁎. Facile synthesis of antioxidative nanotherapeutics using a microwave for efficient reversal of cisplatin-induced nephrotoxicity. Chemical Engineering Journal. 2020, 391,123563.（IF=16.744, A1一区）
4. Haoqiang Lai, Delong Zeng, Chang Liu, Qi Zhang, Xuan Wang, Tianfeng Chen*. Selenium-containing ruthenium complex synergizes with natural killer cells to enhance immunotherapy against prostate cancer via activating TRAIL/FasL signaling. Biomaterials. 2019, 219, 119377.（IF=15.304, A1一区）
5. Haoqiang Lai, Chang Liu, Liyuan Hou, Wenwei Lin, Tianfeng Chen* and An Hong*. TRPM8-regulated calcium mobilization plays a critical role in synergistic chemosensitization of borneol on doxorubicin. Theranostics. 2020, 10, 22. (IF=11.6, A1一区)
6. Jinggong Liu#,Haoqiang Lai#(co-first author),Zushuang Xiong, Bolai Chen and Tianfeng Chen. Functionalization and cancer-targeting design of ruthenium complexes for precise cancer therapy. Chemical Communications. 2019,55, 9094.（IF=6.222, A1二区）
7. Zhen Chen#, Haoqiang Lai#(co-first author), Liyuan Hou, Tianfeng Chen. Rational design and action mechanisms of chemically innovative organoselenium in cancer therapy, Chemical Communications. 2020, 56(2): 179-196.（IF=6.222, A1二区）
8. Guo-Qing Jin#, Haoqiang Lai#(co-first author), Zi-Shu Yang, Yingying Ning,Linqi Duan, Jing Zhang, Tianfeng Chen*, Song Gao, JunLong Zhang*. Gadolinium(III) Porphyrinoid Phototheranostics. Chemistry-An Asian Journal. 2022. e202200181.（IF=4.839, A1二区）
9. Haoqiang Lai#, Xiaoyan Fu#(co-first author), Chengcheng Sang, Liyuan Hou, Pengju Feng, Xiaoling Li, Tianfeng Chen. Selenadiazole Derivatives Inhibit Angiogenesis-Mediated Human Breast Tumor Growth by Suppressing the, Chemistry-An Asian Journal. 2018, 13(11): 1447-1457.（IF=4.839, A1二区）
10. Haoqiang Lai, Xiang Zhang, Pengju Feng, Lina Xie, Jinjin Chen, and Tianfeng Chen*.Enhancement of Antiangiogenic Efficacy of Iron(II) Complex by Selenium Substitution.Chemistry-An Asian Journal. 2017,12,982 –987. （IF=4.839, A1二区, 封面）
11. Haoqiang Lai #, Zhennan Zhao #, Linlin Li, Wenjie Zheng, Tianfeng Chen*. Antiangiogenic ruthenium(II) benzimidazole complexes, structure-based activation of distinct signaling pathways. Metallomics. 2015,7, 439.（IF=4.636, A1二区, 封面）
12. Jianyu Su*#, Haoqiang Lai#(co-first author), Jianping Chen, Yum-Shing Wong, Lin Li, Tianfeng Chen, Xiaoling Li*. Natural Borneol potentiates selenocystine-induced apoptosis in human hepatocellular carcinoma cells by enhancement of cellular uptake and activation of ROS-mediated DNA damage. Plos One. 2013, 8, e63502.（IF=3.757, A1二区）
1. 陈填烽，赖浩强. 右旋龙脑作为阿霉素或其衍生物增敏剂在制备抗肺癌药物中的应用，申请号：201811208471.6
2. 陈填烽、许利耕、赖浩强. 新型冠状病毒蛋白质抗原纳米疫苗及其制备方法和应用，申请号：2021113436894
3. 陈填烽、许利耕、赖浩强. 新型冠状病毒蛋白质抗原纳米疫苗及其制备方法和应用，申请号：PCT2021/130486